

Equity Research Desk

The Indian markets are poised to open Friday's trade on a feeble note, amid subdued global cues. The SGX Nifty was down 67 points at 15,048, at 8.15 AM. Investors may, today, stick to stock-specific trading, while foreign fund flow, the Rupee's trajectory, and oil price movement will also be keenly tracked.

Besides, aviation stocks and telecom stocks will react to their latest monthly air passenger traffic and subscriber data, respectively.

Mahindra CIE Automotive, Asian Tea & Exports & Binani Industries are scheduled to announce their quarterly earnings today.

On Wall Street, the Dow Jones fell 0.38 per cent, the S&P 500 lost 0.44 per cent, and the Nasdaq 0.72 per cent. Asian stocks also pulled back on Friday. Australia's benchmark ASX 200 index and Hong Kong's Hang Seng index dipped over 1 per cent, each, in early trading, while Japan's Nikkei fell 0.9 per cent.

In commodities, Brent crude fell 41 cents, or 0.6 per cent, to settle at \$63.93 a barrel.

Indices	Value	Pts	Chg (%)
SENSEX	51324.69	(379.14)	-0.73
NIFTY	15118.95	(89.95)	-0.59
SGX NIFTY*	15048.00	(67.00)	-0.44
DOW Jones	31493.34	(119.68)	-0.38
S&P	3913.97	(17.36)	-0.44
Nasdaq	13865.36	(100.14)	-0.72
FTSE	6617.15	(93.75)	-1.40
CAC	5728.33	(37.51)	-0.65
DAX	13886.93	(22.34)	-0.16
Shanghai Composite*	3640.99	(34.37)	-0.94
Nikkei*	29947.42	(288.67)	-0.95
Hang Seng*	30209.88	(385.39)	-1.26

Most Active Call & Put					
Symbol	Strike Price	OI (000)	Chg (%)		
NIFTY	15200CE	42875	-33%		
NIFTY	15100PF	49924	74%		

*As at 8.15 am

Commodity	Price	Pts	Chg (%)
NYMEX Crude (USD)	59.40	-1.12	(1.89)
Brent Crude (USD)	62.98	-0.95	(1.51)
Gold (USD)	1763.50	-11.50	(0.65)

Currency	Value	Pts	Chg (%)
USD/Rupee	72.58	3.44	0.05
Euro/Rupee	87.80	0.01	0.00
Pound/Rupee	101.38	0.01	0.00

Indicators	Value	Pts	Chg (%)
India VIX	21.54	0.03	0.14

Indicators	Value	Bps	
India 10-Yr Yield	6.132%	-0.003	
US 10-Yr Yield	1.289%	0.002	

Trade Statistics	BSE	NSE	F & O
Turnover (INR Crs)	4717	81935	8021078
Advance (Nos)	1624	23	NA
Declines (Nos)	1342	27	NA
Unchanged	159	0	NA

Macro News

Air traffic improved by 5.6% in January

Indian airlines flew about 5.6% more domestic passengers in January than in the previous month as travellers turned more confident with the pandemic waning across India.

As many as 7.73 million passengers travelled by air in January, up from 7.33 million in December, data from the Directorate General of Civil Aviation (DGCA) published on Thursday showed. However, this is still 39.50% below the numbers of January 2020.

DGCA has allowed airlines to sell seats up to 80% of an airline's pre-covid capacity on domestic flights since December.

The passenger load factor (PLF) of major scheduled commercial airlines was 64-76% in January, around the same levels recorded in the previous month but way below the 78-91% in the same period of 2020.

In January, IndiGo had a 54.3% market share and 69.3% PLF. It carried 4.20 million passengers. Air India's domestic load factor was at 66.2%, with a market share of 10.3%. The national carrier ferried 797,000 passengers.



Equity Research Desk

Institutional Activity	Cash	
,	18-Feb-21	17-Feb-21
FIIs (INR Crs)		
Buy	9726	8499
Sell	8823	7491
Net	903	1008
DII (INR Crs)		
Buy	5282	4441
Sell	6499	5725
Net	-1217	-1283

FII Derivative Statistics				
Particulars	Buy (INR Crs)	Sell (INR Crs)	OI (Nos)	
INDEX FUTURES	4275	4457	120689	
INDEX OPTIONS	527632	527593	1098367	
STOCK FUTURES	15705	16356	1230510	
STOCK OPTIONS	16242	16338	203671	
Total	563855	564744		

Price	Chg (%)
110 7	0.2
	8.3
	6.47
	4.98
99	4.21
103.4	4.08
63.35	-2.49
23.35	-2.28
364.7	-2.25
	-2.24 -2.21
Pts	Chg (%)
133.14	0.67
139.01	0.69
-333.33	-1.35
-488.37	-1.17
-111.49	-0.50
-38.93	-0.32
-165.50	-0.76
127.64	0.50
164.20	1.27
164.20	1.27
	110.7 143.1 432.2 99 103.4 63.35 23.35 364.7 94.45 45.45 Pts 133.14 139.01 -333.33 -488.37 -111.49 -38.93 -165.50

Key News

Ambuja Cements Q4CY2020 result

On a consolidated basis, the company has reported revenue of Rs.7453 crores during the period ended December 31, 2020 as compared to Rs.7126 crores during the period ended December 31, 2019. OPM during the same period rose 200 bps to 18%. The company has posted net profit of Rs.732 crores for the period ended December 31, 2020 as against net profit of Rs.592 crores for the period ended December 31, 2019.

ACC Q4CY2020 result

On a consolidated basis, the company has reported revenue of Rs.4145 crores during the period ended December 31, 2020 as compared to Rs.4060 crores during the period ended December 31, 2019. OPM during the same period rose 100 bps to 14%. The company has posted net profit of Rs.472 crores for the period ended December 31, 2020 as against net profit of Rs.273 crores for the period ended December 31, 2019.

NMDC'S Donimalai Iron Ore Mine Operations Restarted

After obtaining the Lease extension of Donimalai Iron Ore Mine (ML-2396) for 20 years w.e.f. 03.11.2018 from Govt. of Karnataka (GoK) and completing the associated statutory requirements, the said Donimalai Iron Ore Mine was restarted yesterday.

Poly Medicure Limited prices QIP at Rs. 524 per share

The QIP Committee of board of directors of Poly Medicure has approved closure of the QIP yesterday.

The committee approved the issue price for 76,33,587 Equity Shares to be allotted to eligible qualified institutional buyers at a price of Rs. 524 per Equity Share, including a premium of Rs. 519 per Equity Share, which is at a discount of Rs. 26.79 (4.86% to the floor price of Rs. 550.79 per Equity Share).

IndusInd Bank raises Rs. 2021 crores common equity via conversion of warrants issued to the Promoters

IndusInd Bank raised Rs 2021 crores of common equity capital through conversion of preferential warrants issued to the Promoter entities - IndusInd International Holdings Limited (IIHL) and IndusInd Limited (IL). The warrants were issued as an integral part of the merger with Bharat Financial Inclusion Limited in July 2019. The Promoter entities had paid Rs 673 crores at the time of subscription to the warrants and the balance amount of Rs 2021 crores was paid yesterday.

The finance committee of the Bank today approved allotment of 1,57,70,985 shares to the Promoter entities. The warrants are converted at a price of Rs 1,709 per share reflecting a premium of 65% over the closing price on February 17, 2021.

The Bank's already healthy capital adequacy ratios get further bolstered with this infusion from the Promoter entities. The Capital Adequacy Ratio including 9MFY21 profits was at 16.93% as of December 31, 2020 and this will get augmented to approximately 17.68% with this capital inflow.

Earlier in September 2020, the Bank completed preferential issues of equity capital of Rs 3,288 crores and this was subscribed by the Promoter as well. Together with the current warrants conversion, the Bank has raised Rs 5,309 crores of equity capital during the financial year 2020-21.



Equity Research Desk

Analyst Certification of Independence: The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her Analyst Certification of Independence: The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPA Securities Limited, and have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: SPA Securities Limited (hereinafter refer as SPA Securities) and its affiliates are engaged in investment banking, investment advisory, stock broking, investment advisory, stock broking, investment advisory, stock broking, investment advisory, stock broking investment and broken and provided previously. The provided prov

SPA Securities Limited is registered as a Research Analyst under SEBI (Research Analyst Negations, 2014. Vide SEBI Reg, No. INFl00002615.
We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

General Disclosures: This Research Report (hereinafter called "report") has been prepared by SPA Securities and is meant for sole use by the recipient and not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, (as defined under section 2(h) of securities Contracts (Regulation) Act.1956, through SPA Securities nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments.

This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by SPA Securities to be reliable, although its accuracy and completeness cannot be guaranteed. Such information, internally developed data and other sources believed by correctness. Any eveloped the respective security required from the correctness of the respective security required from the correctness.

information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. Any review, retransmission or any other use is prohibited. The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such

would enleavour to update the imminimation related to the professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither SPA Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any saction taken on basis of this recription, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diministration in the NAVs, reduction in the dividend or income, etc.a.

Commensation of our Research Analysts is not based on any specific merchant banking, investment hanking or brokerage service transactions. SPA Securities may have issued other reports in the past that are inconsistent with and reach

reduction in the dividend or income, etc.a. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPA Securities may have issued other reports in the past that are inconsistent with and reach different conclusion from the information presented in this report.

SPA Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of

India before investing in the Indian Markets.

A graph of daily closing prices of securities is available at www.nseindia.com and http://economictimes.indiatimes.com/markets/stocks/stock-quotes. (Choose a company from the list on the browser and select the "three years" icon in the

Agraph or daily costing prices on securities and account of the securities of the price charty.

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPA Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of SPA Securities.

List of Associates as per SEBI (Research Analyst) Regulations, 2014

Statements on ownership and material conflicts of interest, compensation - SPA and Associates

Disclosure of interest statement	res/No
SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company	No
SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month. Immediately preceding the date of the publication of the research report or date of public appearance.	No
Investment banking relationship with the company covered	No
Any other material conflict of interest at the time of publishing the research report	No
Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months:	
Managing/co-managing public offering of securities	
Investment banking/merchant banking/brokerage services	
products or services other than those above	No
in connection with research report	
Whether Research Analyst has served as an officer, director or employee of the subject company covered	No
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company;	No

For statements on ownership and material conflicts of interest, compensation, etc. for individual Research Analyst(s), please refer to each specific research report.

SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No.: +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

SPA GLOBAL PRIVATE LIMITED

Mutual Fund Advisor AMFI Reg. No. 90796

SPA SECURITIES LTD	SEBI REG. NOS.
NSE Cash	INZ000241036
NSE Future & Option	INZ000241036
NSE Currency Derivatives	INZ000241036
BSE Cash	INZ000241036
BSE Currency Derivatives	INZ000241036
MSEI Cash	INZ000241036
MSEI Future & Option	INZ000241036
MSEI Currency Derivatives	INZ000241036
Mutual Fund	ARN 77388
CDSL DP	IN-DP-CDSL-485-2008
NSDL DP	IN-DP-NSDL-316-2009
SEBI Research Analyst	INH100002615
Merchant Banker	INM000012740